CD8+ TILs mediate most anti-tumor immune responses (Wang et al., 2016), bladder cancer studies also suggest that the presence of CD8+ TILs is associated with favorable prognosis (Sharma et al., 2007; Faraj et al., 2015). The gene discussed is CD8A; the disease is urinary bladder carcinoma.